99%+ Purity
COA Included
Sealed Vials
Tirzepatide
Dual GLP-1/GIP agonist for enhanced metabolic control
GLP/GIP dual agonist
Key Benefits
- Dual receptor targeting for enhanced efficacy
- Glucose-dependent insulin stimulation mechanism
- Extended half-life enabling weekly dosing
- Superior outcomes versus single-hormone therapies
- Supports appetite regulation and satiety
- Enhanced insulin sensitivity at cellular level
- FDA-approved with established safety profile
Control Your Appetite While Your Body Burns Fat
Most weight loss approaches make you fight constant hunger while your metabolism slows down. Tirzepatide flips this entirely—it naturally suppresses your appetite while keeping your metabolic rate high. You lose weight without the mental torture of traditional dieting.
Dual GLP-1/GIP receptor activation for glucose regulation and appetite control
About Tirzepatide
Tirzepatide is a dual-action peptide that targets two key metabolic receptors simultaneously, providing superior glucose control and weight management compared to single-pathway approaches. It stimulates insulin release only when blood sugar is elevated while significantly reducing appetite and slowing gastric emptying. The extended half-life allows for convenient weekly dosing with sustained metabolic benefits throughout the dosing interval.
Who It's For
Designed for individuals seeking comprehensive metabolic optimization without the drawbacks of traditional weight loss methods. This represents the most advanced approach to sustainable body composition changes, particularly valuable for those who have struggled with appetite control or metabolic dysfunction. Tirzepatide fits into long-term protocols as a foundational tool for maintaining lean body mass while achieving significant fat loss.
Research Background
Tirzepatide represents a breakthrough in dual incretin hormone therapy, targeting two key metabolic pathways simultaneously. The incretin system consists of hormones released from the intestine in response to food intake, with GLP-1 and GIP being the primary regulators of post-meal blood sugar control. While traditional diabetes medications often focus on single pathways, tirzepatide's innovative dual-receptor approach addresses multiple aspects of metabolic dysfunction including: 1) glucose-dependent insulin release (insulin is only released when blood sugar is elevated), 2) suppression of excess glucose production by the liver, and 3) delayed gastric emptying which promotes satiety and weight loss.
Research has primarily focused on type 2 diabetes management and obesity treatment, with clinical trials demonstrating superior outcomes compared to existing single-hormone therapies. The unique molecular design includes modifications that extend the peptide's duration of action, allowing for convenient weekly injections rather than daily dosing. Current research directions include investigating cardiovascular benefits, potential applications in liver disease, and optimization of dosing strategies to maximize therapeutic benefits while minimizing side effects.
Dosing Protocol
| Level | Dose | |
|---|---|---|
Beginner | 2.5 mg/wk | |
Intermediate | 5 mg/wk | |
Advanced | 10-15 mg/wk | |
Maximum | 20-25 mg/wk |
Select a dosing level and click Calculate to plan your protocol.
Vials Required
6
60.0 mg needed ÷ 10 per vial
Total Investment
$450
$75.00 per vial
Per Dose
0.50 mL
50 units on U-100 syringe
Doses per Vial
2
10 ÷ 5.00 mg/dose
* Calculations based on standard reconstitution protocols. Consult research guidelines for specific applications.
Compliance & Disclaimer
This product is intended for laboratory research purposes only. Not for human consumption. All products are sold with the understanding that the purchaser will comply with all applicable local, state, and federal laws regarding the purchase and use of research chemicals. Certificate of Analysis available upon request.
Tirzepatide
$75.00